{"prompt": "['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 71 of 92', 'CR845-CLIN3102', 'change from baseline score. Baseline is defined as the last measurement taken on or prior', 'to the first day of dosing. Note that the Day 1 assessment can be included in the', 'evaluation of baseline if that the assessment is performed prior to dosing.', 'If or more evaluations occur in the same visit window, the evaluation closest to the', 'target visit day will be selected for inclusion in the analysis. If multiple evaluations are', 'equally close to the target visit day, then the latest evaluation will be selected for', 'inclusion in the analysis.', 'All vital sign summaries will include the patients in the Double-blind Safety Population', 'who have at least a postbaseline time point (for criteria based on postbaseline', 'assessments) and with both a baseline and at least 1 postbaseline time point (for criteria', 'evaluating changes from baseline). >', 'Clinically notable vital signs will be identified based on the criteria in Table 6. For each', 'vital sign parameter, the number and percentage of patients with at least 1 notable value', 'will be tabulated by week and overall for the Double-blind Phase.', 'Table 6.', 'Criteria Used to Identify Clinically Notable Vital Sign', 'Abnormalities', 'Vital Sign Parameter', 'Value', 'Change from Baselinea', 'Systolic blood pressure', '>180 mm Hg', 'Increase or Decrease of >40 mm Hg', '<90 mm Hg', 'Decrease of >60 mm Hg', 'Diastolic blood pressure', '>100 mm Hg', 'Increase or Decrease of >20 mm Hg', '<60 mm Hg', 'Decrease of >40 mm Hg', 'Heart rate', '>130 bpm', 'Increase of >30 bpm', '<55 bpm', 'Decrease of >30 bpm', 'a.', 'Both value and change from baseline criteria must be met to qualify as a clinically notable', 'abnormality.', 'All vital signs will be listed in by-patient listings, including visit and collection date/time,', 'and will be sorted by patient identifier and date/time of assessment.', 'Electrocardiogram results include an overall interpretation of \"normal, \\'abnormal but not', \"clinically significant,' or 'abnormal and clinically significant. These results will be\", 'tabulated at each time point.', 'Electrocardiogram results will be listed for each visit, including visit, whether ECG was', 'performed (yes/no), explanation (if not performed), assessment date/time, study date,', 'overall interpretation, and relevant medical history number or adverse event number, if', 'deemed a clinically significant abnormality.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 73 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 72 of 92', 'CR845-CLIN3102', '8.9', 'Additional Analyses', '8.9.1', 'Inflammatory Biomarkers', 'The observed value and the change in inflammatory biomarkers (eg, IL-6, IL-8, and', 'granulocyte macrophage-colony stimulating factor) from pre-dose to the end of the', 'Double-blind Treatment Period (Week 12) will be presented by treatment group.', 'Univariate and multivariate analyses of the change in inflammatory biomarkers will be', 'described in an analysis plan, separate from the study SAP.', '8.9.2', 'Missed Dialysis Visits and Incidence of Infection', 'The number and percentage of patients who missed 1 or more dialysis visits during the', 'Double-blind Treatment Period, and the total number of missed dialyses visits will be', 'tabulated overall and by treatment group.', 'Incidence of infections based on adverse events, hospitalizations, and/or use of antibiotics', \"for treatment of infection related to uremic pruritus will be analyzed using Fisher's Exact\", 'Test.', '8.9.3', 'ESA and IV Iron', 'Erythropoiesis-stimulating agent and IV Iron use will be summarized descriptively by', 'treatment group. Statistical analyses of changes in use of ESAs or IV iron from pre-dose', 'to the end of the Double-blind Treatment Period (Week 12) will be defined in the SAP.', '8.9.4', 'Discontinuation Period Additional Assessments', 'Baseline ShOWS and OOWS will be the scores collected on the dialysis day on Day 85', '(Double-blind EOT/Early Termination) (Table 2). Only patients who have a baseline', 'ShOWS and OOWS will be included in the analysis.', 'Summary statistics for the daily ShOWs and the OOWS collected at each dialysis visit,', 'including number of non-missing observations, mean, standard deviation, median,', 'minimum, and maximum median of ShOWS and OOWS will be tabulated by treatment', 'group. Figures for the overall mean scores over time will also be presented.', 'The ShOWS scores on discontinuation days 1, 2, 3, and >3 will be analyzed to compare', 'the treatment groups at each visit, using an Analysis of Covariance (ANCOVA) model,', 'with treatment group and baseline value as a covariate. The OOWS scores will be', 'analyzed using a similar ANCOVA model at each day of collection. In addition,', 'between-treatment group comparisons over the overall 2-Week Discontinuation Period', 'will be performed using an MMRM with treatment group, discontinuation day, and', 'treatment group-by-day interaction as fixed effects, baseline value as the covariate, and', 'patient as a random effect. An unstructured covariance matrix will be used to model the', 'covariance of within-patient scores. These analyses will be performed based on all', 'postbaseline scores using only the observed cases without imputation of missing values.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 74 of 95']\n\n###\n\n", "completion": "END"}